Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1375486rdf:typepubmed:Citationlld:pubmed
pubmed-article:1375486lifeskim:mentionsumls-concept:C0033325lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0023165lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0205851lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0205070lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0405581lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C2698872lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0475276lld:lifeskim
pubmed-article:1375486lifeskim:mentionsumls-concept:C0021212lld:lifeskim
pubmed-article:1375486pubmed:issue2-3lld:pubmed
pubmed-article:1375486pubmed:dateCreated1992-6-26lld:pubmed
pubmed-article:1375486pubmed:abstractText44 patients with metastatic testicular germ cell tumours treated with cisplatin-based chemotherapy were evaluated for prognostic implications of clinical characteristics. 22 obtained complete remission by the initial chemotherapy, and 30 are disease-free. S-LDH-1 had an overall predictive value regarding the response of 80%, S-LDH of 64%, S-AFP of 62%, and S-hCG of 62%. In multivariate analysis regarding response, only tumour volume classified according to the Royal Marsden system (P = 0.0036) and S-LDH-1 (P = 0.0069) yielded information. Regarding survival, S-LDH-1 (P = 0.0141) and an estimate of total tumour mass (P = 0.0171) had most impact with additional information from S-hCG only (P = 0.0536). We conclude that S-LDH-1 may be used as a tumour marker in addition to S-hCG and S-AFP in patients with metastatic testicular germ cell tumour.lld:pubmed
pubmed-article:1375486pubmed:languageenglld:pubmed
pubmed-article:1375486pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1375486pubmed:citationSubsetIMlld:pubmed
pubmed-article:1375486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1375486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1375486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1375486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1375486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1375486pubmed:statusMEDLINElld:pubmed
pubmed-article:1375486pubmed:issn0959-8049lld:pubmed
pubmed-article:1375486pubmed:authorpubmed-author:GullbergBBlld:pubmed
pubmed-article:1375486pubmed:authorpubmed-author:BlaabjergOOlld:pubmed
pubmed-article:1375486pubmed:authorpubmed-author:PetersenP HPHlld:pubmed
pubmed-article:1375486pubmed:authorpubmed-author:MadsenE LELlld:pubmed
pubmed-article:1375486pubmed:authorpubmed-author:von EybenF...lld:pubmed
pubmed-article:1375486pubmed:authorpubmed-author:Smith-Siverts...lld:pubmed
pubmed-article:1375486pubmed:issnTypePrintlld:pubmed
pubmed-article:1375486pubmed:volume28lld:pubmed
pubmed-article:1375486pubmed:ownerNLMlld:pubmed
pubmed-article:1375486pubmed:authorsCompleteYlld:pubmed
pubmed-article:1375486pubmed:pagination410-5lld:pubmed
pubmed-article:1375486pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:meshHeadingpubmed-meshheading:1375486-...lld:pubmed
pubmed-article:1375486pubmed:year1992lld:pubmed
pubmed-article:1375486pubmed:articleTitleSerum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in metastatic testicular germ cell tumours.lld:pubmed
pubmed-article:1375486pubmed:affiliationDepartment of Internal Medicine, Central Hospital, Nykøbing Falster, Denmark.lld:pubmed
pubmed-article:1375486pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1375486pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed